pramipexole has been researched along with clozapine in 11 studies
| Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (clozapine) | Trials (clozapine) | Recent Studies (post-2010) (clozapine) |
|---|---|---|---|---|---|
| 1,103 | 219 | 517 | 9,691 | 747 | 3,148 |
| Protein | Taxonomy | pramipexole (IC50) | clozapine (IC50) |
|---|---|---|---|
| Adenylate cyclase type 1 | Rattus norvegicus (Norway rat) | 0.14 | |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.032 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.47 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.476 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.045 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.1233 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.1534 | |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.15 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.031 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.013 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.09 | |
| Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | 0.14 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0096 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.2044 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0886 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.023 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0079 | |
| D | Rattus norvegicus (Norway rat) | 1.066 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.2695 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 1.804 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.078 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.107 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.0796 | |
| Adenylate cyclase type 3 | Rattus norvegicus (Norway rat) | 0.14 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.47 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 5.7544 | |
| Histamine H2 receptor | Homo sapiens (human) | 3.61 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.035 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| Adenylate cyclase type 2 | Rattus norvegicus (Norway rat) | 0.14 | |
| Adenylate cyclase type 4 | Rattus norvegicus (Norway rat) | 0.14 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0658 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0658 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.373 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.587 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.587 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0338 | |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.023 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.546 | |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.028 | |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.028 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.0049 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.354 | |
| Adenylate cyclase type 8 | Rattus norvegicus (Norway rat) | 0.14 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.081 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0171 | |
| D(2) dopamine receptor | Mus musculus (house mouse) | 0.29 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.6759 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.028 | |
| Adenylate cyclase type 6 | Rattus norvegicus (Norway rat) | 0.14 | |
| Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | 0.14 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4162 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 3.6 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 2 | |
| Adenylyl cyclase 7 | Rattus norvegicus (Norway rat) | 0.14 | |
| D | Bos taurus (cattle) | 4.09 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fici, GJ; Sethy, VH; VonVoigtlander, PF; Wu, H | 1 |
| Kołodziejczyk, K; Maj, J; Rogóz, Z; Skuza, G | 1 |
| Conca, A; Eiler, M; Rehor, G | 1 |
| Barsoum, P; Graff-Guerrero, A; Houle, S; Kapur, S; Mamo, D; Marcon, H; Mizrahi, R; Rusjan, P; Shammi, CM; Wilson, AA | 1 |
| Bosco, D; Bosco, F; Consoli, A; Plastino, M; Rotondo, A | 1 |
| Adriana, S; John, AP; La'Brooy, JA; Piepiorka-Sokolowska, D | 1 |
| Amador, EC; Cunningham, EA; Olabisi, JL | 1 |
1 review(s) available for pramipexole and clozapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for pramipexole and clozapine
| Article | Year |
|---|---|
The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzodiazepines; Benzothiazoles; Binding, Competitive; Carbon Radioisotopes; Caudate Nucleus; Clozapine; Dopamine Agonists; Dopamine Antagonists; Double-Blind Method; Female; Globus Pallidus; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Olanzapine; Oxazines; Positron-Emission Tomography; Pramipexole; Putamen; Raclopride; Receptors, Dopamine D2; Receptors, Dopamine D3; Risperidone; Schizophrenia | 2009 |
9 other study(ies) available for pramipexole and clozapine
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
D1 dopamine receptor activity of anti-parkinsonian drugs.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Apomorphine; Benzazepines; Benzothiazoles; Bromocriptine; Cells, Cultured; Cerebellum; Clozapine; Cyclic AMP; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Tetrahydronaphthalenes; Thiazoles | 1997 |
The behavioural effects of pramipexole, a novel dopamine receptor agonist.
Topics: Animals; Antiparkinson Agents; Benzazepines; Benzothiazoles; Body Temperature; Catalepsy; Clozapine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Haloperidol; Injections, Subcutaneous; Levodopa; Male; Mice; Motor Activity; Pramipexole; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Spiperone; Stereotyped Behavior; Sulpiride; Thiazoles | 1997 |
[D3 agonism: an augmentative treatment in tardive dyskinesia? A case report].
Topics: Adjustment Disorders; Aggression; Antipsychotic Agents; Benzothiazoles; Clozapine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Intellectual Disability; Male; Pramipexole; Receptors, Dopamine D3; Social Behavior Disorders; Young Adult | 2008 |
Clozapine for medication-related pathological gambling in Parkinson disease.
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Clozapine; Ergolines; Female; Gambling; Humans; Male; Middle Aged; Parkinson Disease; Pramipexole; Selegiline; Serotonin Antagonists | 2010 |
Successful treatment of clozapine-associated restless leg syndrome with pramipexole.
Topics: Adult; Antipsychotic Agents; Benzothiazoles; Clozapine; Dopamine Agonists; Female; Humans; Pramipexole; Restless Legs Syndrome; Treatment Outcome | 2014 |
Schizophrenia With Decompensation on Clozapine With Pramipexole.
Topics: Antipsychotic Agents; Clozapine; Dopamine Agonists; Female; Humans; Middle Aged; Pramipexole; Restless Legs Syndrome; Schizophrenia | 2019 |